The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Recap by typeshit. Full story at The Pharma Letter.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Social media promoters claim peptides speed healing, smooth skin and extend life, and CBS notes the HHS Secretary counts himself a fan.
A short teaser points to another reported side effect of GLP-1 drugs but doesn't say what it is.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Loading…